DOW JONES27,578.86-381.94 -1.37%
S&P 5003,180.13-45.76 -1.42%
NASDAQ9,116.94-104.34 -1.13%

Roth Capital Initiates Coverage On INmune Bio with Buy Rating, Announces $13 Price Target

Roth Capital analyst Jonathan Aschoff initiates coverage on INmune Bio (NASDAQ:INMB) with a Buy rating and a $13 price target.

Benzinga · 12/19/2019 11:18

Roth Capital analyst Jonathan Aschoff initiates coverage on INmune Bio (NASDAQ:INMB) with a Buy rating and a $13 price target.